METHODS
This retrospective review included all consecutive survivors seen in
Memorial Sloan Kettering (MSK)’s Pediatric LTFU Clinic between May
5–September 10, 2020, which provides risk-based care to survivors of
childhood cancer and HCT diagnosed at age ≤18 who are ≥1-year
off-therapy at program entry.
All patients were scheduled for routine LTFU (in-person or via
telehealth) during this interval; SARS-CoV-2 IgG testing was offered
when venipuncture was being performed for clinical
indications.7,8 During all visits, patients were
assessed for known COVID-19 exposure(s) after March 1, 2020; COVID-19
related symptoms [fever, cough, respiratory distress, loss of
smell/taste]; and COVID-19-related hospitalization. A subset of
patients had SARS-CoV-2 PCR testing performed locally or on-site if they
had traveled from high-prevalence areas, reported active symptoms of
infection, or required testing for preprocedural
indications.9
The protocol was approved by the MSK Institutional Review/Privacy Board.